Navigation Links
VTT: No significant difference in car fuel consumption between E10 and E5 petrol grades
Date:6/6/2011

A study conducted by VTT Technical Research Centre of Finland indicates that there is practically no difference between commercial petrol grades 95E10 and 98E5 sold in Finland as regards fuel consumption in normal driving. The finding is based on driving tests conducted by VTT using six used cars of different make under laboratory conditions.

It has been frequently claimed in public that fuel consumption is significantly higher with 95E10 petrol than with its predecessor 95E or the 98E5 petrol currently on the market. The suspected higher consumption has deterred drivers of cars whose manufacturers recommend E10 from actually using it.

"The point of this study was to highlight how fuel consumption should actually be measured to give comparable results. Measuring fuel consumption very accurately is not as simple as it seems, because other factors affect consumption besides the fuel itself. In laboratory conditions, we can eliminate these other factors," says Juhani Laurikko, a Principal Scientist at VTT.

The VTT measurements show that the cars tested used an average of 10.30 litres of 95E10 per 100 km, as opposed to 10.23 litres of 98E5 per 100 km. The difference was 0.07 in favour of 98E5 on average, meaning that using 95E10 petrol, which has a higher ethanol content, increases consumption by 0.7%. Normalising measurement results of each individual test run with observed slight scatter in actual total work done over the driving cycle yields to somewhat higher overall difference, 1.0%.

An estimation of calorific values based on approximate fuel composition came out at 1.1% in favour of E5, which is highly consistent with the aforementioned 1.0% difference in consumption. Fuel consumption depends mainly on the calorific value of the fuel, i.e. its energy content per unit of volume or mass.

See tables: Tabel 1: Cars used in the tests and Table 2: Summary of test results: http://www.vtt.fi/files/news/2011/E-10/E10-tables.pdf

How was the study conducted?

VTT obtained all the fuel used for the test runs at the same time from the Otaniemi Neste Oil service station in Espoo. So as to ensure that ethanol contents was in accordance with the specifications, the ethanol contents of both fuel batches was determined by the Finnish Customs Laboratory. The results showed 4.7% for the E5-grade and 9.4% for the E10 grade.

VTT performed the comparison test under controlled laboratory conditions, because of practical and almost unsurmountable difficulties in measuring a car's fuel consumption accurately and repeatability in normal driving. Therefore, the public claims concerning differences in fuel consumption may be due to any number of other factors besides the type of fuel used.

The study involved six petrol-driven cars loaned by VTT employees. The cars were of model years between 1999 and 2010 and, according to their manufacturers' recommendations, compatible with E10-fuel. The cars were checked to ensure they were free of any faults or malfunctions that could have influenced the test results.

VTT measured fuel consumption using the simplest and most reliable method: measuring the weight of fuel consumed. As the density of the fuel grades was known, establishing the volume of fuel consumed was a simple matter.

The driving programme used for the test drives was the FTP72 programme, which features more aggressive accelerations and a high average speed than corresponding EU cycle. Two drivers were used for the tests, both of them experienced and qualified for conducting accredited exhaust emission tests. Each car was driven by the same driver in all tests. Two tests were conducted on consecutive days for each petrol grade. The running order of the fuels was random.


'/>"/>

Contact: Juhani Laurikko
juhani.laurikko@vtt.fi
358-207-225-463
VTT Technical Research Centre of Finland
Source:Eurekalert

Related biology news :

1. Significant role of oceans in onset of ancient global cooling
2. Drug therapy shows significant benefit in treating a leading cause of childhood blindness
3. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
4. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
5. New study shows soy protein lowers non-HDL cholesterol significantly more than milk protein
6. Slight change in wind turbine speed significantly reduces bat mortality
7. Significant weight-loss from surgery decreases risk for cardiovascular disease in women
8. Fractures significantly reduce quality of life in women with osteoporosis
9. Online release of North American industrial pollution data reveals significant reporting gaps
10. Scientists identify seamounts as significant, unexplored territory
11. Significant findings about protein architecture may aid in drug design, generation of nanomaterials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... Intoxalock, a leading ignition interlock provider, has ... patent-pending calibration device. With this new technology, Intoxalock is ... data logs and process repairs at service center locations, ... drunk driving through the application of cutting-edge technologies is ... also for the customer who can get back on ...
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers ... research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of the latest paper by its Science Editor, Dr. Elisabeth Bik, in the ... Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from her previous position ...
(Date:1/18/2017)... 2017 Shareholder rights law firm Johnson & ... board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... the proposed sale of the Company to Eli Lilly ... small molecules for the acute treatment of migraines. ... signed a definitive merger agreement with Eli Lilly. Under ...
(Date:1/18/2017)... 2017  Caris Life Sciences, a leading innovator ... largest private funder of pancreatic cancer research, are ... impact of immunotherapy in the treatment of pancreatic ... to identify potential trial candidates based on biomarker ... and study investigators. The Lustgarten Foundation is a ...
Breaking Biology Technology: